Associate Professor Richard Haynes
|Tel||+44 (0)1865 743607|
- MRC Project Leader Track
- MSc in Global Health Science module 8 lead: Clinical Trials and Meta-Analysis
Richard Haynes did his pre-clinical medical studies in Cambridge before moving to Oxford for his clinical studies and qualified in 2000. He came to CTSU for a period of “out of programme” research in 2006 to work on the HPS2-THRIVE trial with Prof Jane Armitage. He completed his training in renal medicine in 2011 and was appointed as an honorary consultant at the Oxford Kidney Unit. Shortly after that he was appointed to the MRC Programme Leader track and he now works on randomized trials and epidemiology (particularly in renal medicine and cardiovascular disease) at CTSU.
A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
Schlackow I. et al, (2017), Heart
Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.
Mafham MM. et al, (2017), Nephrol Dial Transplant
Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP).
Staplin N. et al, (2016), American Journal of Kidney Diseases, 68, 371 - 380
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
Herrington W. et al, (2016), The Lancet Diabetes and Endocrinology
The Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin with Laropiprant on Health and Healthcare Costs
Mihaylova BN. et al, (2016), Circulation: Cardiovascular Quality and Outcomes